- $12.45m
- -$302.20m
- $213.65m
Brief: Amarin Says Scottish Medicines Consortium Accepts Vazkepa To Help Reduce Cardiovascular Risk
Amarin Corporation PLC reports results for the quarter ended in June - Earnings Summary
Brief: Amarin Q2 Product Revenue USD 65.187 Mln
Amarin Corporation PLC expected to post a loss of 4 cents a share - Earnings Preview
Brief: Amarin And Lotus Pharmaceuticals Announce Exclusive Partnership In Southeast Asia And South Korea
Brief: Amarin Receives Positive Recommendation From Spanish Drug Pricing Committee For National Reimbursement Of Heart Drug
Amarin announces restructuring plan, new CEO; shares drop on weak Vascepa rev
Brief: Amarin Corporation PLC Estimates That It Will Incur About $10 Mln In Charges Related To Organizational Restructuring Program
Brief: Amarin Appoints Patrick Holt As President And Chief Executive Officer
Brief: Amarin Implements Organizational Restructuring To Strengthen The Company While Driving Patient Access To Vascepa/Vazkepa Globally
Brief: Amarin Corporation PLC Vascepa Approved To Reduce Cardiovascular Risk In Kingdom Of Saudi Arabia
U.S. STOCKS ON THE MOVE-Lands' End, Energy sector
U.S. STOCKS ON THE MOVE-Biogen, NetApp, LyondellBasell
Amarin Corp rises as partner receives approval for heart drug in China
Brief: Amarin Partner Eddingpharm Receives Regulatory Approval For Vascepa In Mainland China
Amarin Corporation PLC reports results for the quarter ended in March - Earnings Summary
Brief: Amarin Reports First Quarter 2023 Loss Per Share $0.04
Amarin Corporation PLC expected to post a loss of 3 cents a share - Earnings Preview
Brief: Amarin Names Aaron Berg Interim President & Chief Executive Officer And Adds Oliver O'connor To Company's Board Of Directors